|Table of Contents|

Targeting SECTM1 to inhibit the malignant phenotype induced by low-concentration of Palbociclib in lung adenocarcinoma cells

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 17
Page:
3227-3233
Research Field:
Publishing date:

Info

Title:
Targeting SECTM1 to inhibit the malignant phenotype induced by low-concentration of Palbociclib in lung adenocarcinoma cells
Author(s):
KONG Pengzhou1; 2; 3; YANG Xin1; 2
1.Translational Medicine Research Center,Shanxi Medical University,Shanxi Taiyuan 030001,China;2.Key Laboratory of Cellular Physiology of the Ministry of Education & Department of Pathology,Shanxi Medical University,Shanxi Taiyuan 030001,China;3.Department of Respiratory and Critical Care Medicine,the First Hospital of Shanxi Medical University,NHC Key Laboratory of Pneumoconiosis,Shanxi Taiyuan 030001,China.
Keywords:
lung adenocarcinoma; Palbociclib; cytokine; SECTM1
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.17.010
Abstract:
Objective:To investigate the reversal effect of knockdown of secreted and transmembrane 1（SECTM1) on the malignant phenotype of lung adenocarcinoma cells induced by low-concentration of Palbociclib（Pb),a cell cycle selective inhibitor.Methods:The killing effect of different concentrations of Pb on lung adenocarcinoma cell line H1650 was detected using CCK8.Transwell chamber experiment was used to detect the invasion and migration ability of H1650 cells after 2 μmol/L Pb treatment.Bioinformatics analysis was used to analyze transcriptome expression changes and screen for differentially expressed genes after 2 μmol/L Pb treatment to H1650 cells.The effect of Pb on the expression level of SECTM1 in H1650 cells was verified.The effect of SECTM1 knockdown on the malignant phenotype and epithelial-mesenchymal transition（EMT) markers induced by low-concentration of Pb was further detected.Results:Pb inhibited the growth of H1650 cells but 2 μmol/L Pb promoted their invasion and migration abilities.The sequencing results showed that 2 μmol/L Pb inhibited the cell cycle related signaling pathways in lung adenocarcinoma cells,but activated the cytokine-cytokine receptor interaction pathway.Knockdown of SECTM1 significantly reversed the increase in low-concentration of Pb-induced invasion and migration abilities and decreased the expression of EMT markers.Conclusion:Low-concentration of Pb may induce increased invasion and migration ability of LUAD cells,and targeting SECTM1 might inhibit its side effects.

References:

［1］SIEGEL RL,GIAQUINTO AN,JEMAL A.Cancer statistics,2024［J］.CA Cancer J Clin,2024,74(1):12-49.
［2］郑荣寿，张思维，孙可欣，等.2016年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志,2023,45(3):212-220. ZHENG RS,ZHANG SW,SUN KX,et al.Cancer statistics in China，2016［J］.China J Oncol,2023,45(3):212-220.
［3］EDELMAN MJ,REDMAN MW,ALBAIN KS,et al.SWOG S1400C（NCT02154490)-a phase Ⅱ study of palbociclib for previously treated cell cycle gene alteration-positive patients with stage Ⅳ squamous cell lung cancer（lung-map substudy)［J］.J Thorac Oncol,2019,14(10):1853-1859.
［4］SUMI NJ,KUENZI BM,KNEZEVIC CE,et al.Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4/6 inhibitors in lung cancer［J］.ACS Chem Biol,2015,10(12):2680-2686.
［5］KONG P,YANG X,ZHANG Y,et al.Palbociclib enhances migration and invasion of cancer cells via senescence-associated secretory phenotype-related CCL5 in non-small cell lung cancer［J］.J Oncol,2022,2022:2260625.
［6］杨昕，徐晓琴，孔鹏洲.食管鳞癌细胞自分泌白介素-32通过诱导上皮间质转化促进肿瘤恶性表型［J］.现代肿瘤医学,2022,30(12):2114-2119. YANG X,XU XQ,KONG PZ.Autocrine interleukin-32 from esophageal squamous cell carcinoma cells promotes malignant phenotype of cancer cells via inducing epithelial-mesenchymal transition［J］.Modern Oncology,2022,30(12):2114-2119.
［7］HANAHAN D,WEINBERG RA.Hallmarks of cancer:The next generation［J］.Cell,2011,144(5):646-674.
［8］MALUMBRES M,BARBACID M.Cell cycle,CDKs and cancer:A changing paradigm［J］.Nat Rev Cancer,2009,9(3):153-166.
［9］GOEL S,DECRISTO MJ,MCALLISTER SS,et al.CDK4/6 inhibition in cancer:Beyond cell cycle arrest［J］.Trends Cell Biol,2018,28(11):911-925.
［10］DU Q,GUO X,WANG M,et al.The application and prospect of CDK4/6 inhibitors in malignant solid tumors［J］.J Hematol Oncol,2020,13(1):41.
［11］RENCUZOGULLARI O,YERLIKAYA PO,GURKAN AC,et al.Palbociclib,a selective CDK4/6 inhibitor,restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells［J］.J Cell Biochem,2020,121(1):508-523.
［12］QIN Q,LI X,LIANG X,et al.Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer［J］.Thorac Cancer,2021,12(11):1708-1715.
［13］LIU F,KORC M.CDK4/6 inhibition induces epithelial mesenchymal transition and enhances invasiveness in pancreatic cancer cells［J］.Mol Cancer Ther,2012,11(10):2138-2148.
［14］宋彬，刘祥辰，董慧玲.低浓度帕博西尼诱导食管鳞癌细胞发生上皮-间质转化的实验研究［J］.临床肿瘤学杂志,2021,26(5):398-403. SONG B,LIU XC,DONG HL.Epithelial-mesenchymal transition of esophageal squamous cell carcinoma cells induced by low concentration of Palbociclib［J］.Chinese Clinical Oncology,2021,26(5):398-403.
［15］SLENTZ-KESLER KA,HALE LP,KAUFMAN RE.Identification and characterization of K12（SECTM1),a novel human gene that encodes a Golgi-associated protein with transmembrane and secreted isoforms［J］.Genomics,1998,47(3):327-340.
［16］LYMAN SD,ESCOBAR S,ROUSSEAU AM,et al.Identification of CD7 as a cognate of the human K12（SECTM1) protein［J］.J Biol Chem,2000,275(5):3431-3437.
［17］HUYTON T,GOTTMANN W,BADE-DODING C,et al.The T/NK cell co-stimulatory molecule SECTM1 is an IFN "early response gene" that is negatively regulated by LPS in human monocytic cells［J］.Biochim Biophys Acta,2011,1810(12):1294-1301.
［18］WANG T,HUANG C,LOPEZ-CORAL A,et al.K12/SECTM1,an interferon-gamma regulated molecule,synergizes with CD28 to costimulate human T cell proliferation［J］.J Leukoc Biol,2012,91(3):449-459.
［19］MEI J,FU Z,CAI Y,et al.SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers［J］.iScience,2023,26(2):106027.
［20］WANG T,GE Y,XIAO M,et al.SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated activation of the PI3K pathway［J］.J Invest Dermatol,2014,134(4):1108-1118.

Memo

Memo:
National Natural Science Foundation of China(No.82072746);国家自然科学基金资助项目(编号：82072746);中央级公益性科研院所科研业务项目(编号：2020-PT320-005)；国家卫生健康委尘肺病重点实验室开放课题（编号：NHC202315）
Last Update: 2024-07-31